This page addresses the evidence-based management of viable parenchymal neurocysticercosis (NCC) presenting with 1–2 viable parenchymal cysticerci in the absence of elevated intracranial pressure — a clinically defined subset with specific treatment recommendations.
Viable parenchymal neurocysticercosis with 1–2 viable parenchymal cysticerci and no elevated intracranial pressure. The absence of elevated intracranial pressure is a key condition enabling the antiparasitic treatment approach described in this protocol.
Management centres on antiparasitic monotherapy combined with adjunctive corticosteroid therapy initiated before the antiparasitic agent — with additional management considerations for patients who present with seizures.
The specific agents, dosing, duration, and complete sequenced regimen are available in the full structured protocol →
Radiologic resolution of the parenchymal cystic component on MRI, assessed at follow-up by 6 months.
DOI: 10.1093/cid/cix1084
In the absence of elevated intracranial pressure, we recommend use of antiparasitic drugs in all patients with VPN (strong, moderate).
For patients with 1–2 viable parenchymal cysticerci, we recommend albendazole monotherapy for 10–14 days compared to either no antiparasitic therapy (strong, high) or combination antiparasitic therapy (weak, low).
We recommend adjunctive corticosteroid therapy begun prior to antiparasitic drugs rather than no adjunctive therapy in all patients treated with antiparasitic therapy (strong, moderate).
We recommend antiepileptic drugs in all NCC patients with seizures (strong, low).
We suggest that MRI be repeated at least every 6 months until resolution of the cystic component (strong, low).
View source ↗